We are watching a major shift in how scientists understand and treat major depressive disorder. For decades, most depression treatments focused on the monoamine system, which includes serotonin, dopamine, and norepinephrine. Medications like SSRIs can help many people, but they act slowly and often take weeks to show meaningful improvement. For individuals in severe distress, the delay can be difficult, and up to half of patients do not fully respond.
In recent years, a different pathway has gained attention: the glutamate system. Medications that interact with glutamate signaling seem to produce much faster mood improvements. Ketamine, psilocybin, and now nitrous oxide all fall into this category. These agents may offer relief within hours instead of weeks.
Why Researchers Are Studying Nitrous Oxide for Depression
Nitrous oxide for depression may sound surprising at first. Many people associate it with dental procedures or recreational misuse. Yet the scientific rationale is stronger than it appears. Nitrous oxide is an NMDA receptor antagonist, similar to ketamine, which helps explain its potential antidepressant effects. It also lightly stimulates opioid receptors and may influence brain networks involved in self-awareness and rumination.
Animal studies suggest nitrous oxide may reduce activity in the default mode network, a brain circuit that supports repetitive self-focused thinking. Rumination is a core feature of depression, and reducing its intensity could offer therapeutic benefits.
What the New Meta Analysis Found on Nitrous Oxide for Depression
A recent meta-analysis published in eBioMedicine combined seven randomized trials exploring nitrous oxide for depression. Although the total number of participants was small, the findings were encouraging. Most studies used a mixture of 50 percent nitrous oxide and oxygen, compared to a control of plain air or oxygen alone.
Five of the seven studies showed significant reductions in depression symptoms. Another showed borderline improvement, and one without a control group still reported noticeable symptom drops. The effects appeared within one hour and continued through 24 hours after treatment. However, the benefits faded by the one week mark, suggesting that nitrous oxide may work best as a short-term or repeated therapy, similar to ketamine protocols.
The Biggest Challenge: Blinding in Nitrous Oxide Research
A major limitation across these studies is the difficulty of blinding participants. It is almost impossible to disguise whether someone is inhaling nitrous oxide or plain air. In one study, around three quarters of participants correctly guessed their treatment group. When outcomes rely on subjective self-reported mood scales, this creates risk that placebo effects may inflate results.
Ketamine and psilocybin studies share this challenge, and researchers are considering creative solutions. One proposal is administering treatments while participants are under brief anesthesia, so they cannot detect which drug they received. Though difficult to conduct, this approach could help clarify whether the antidepressant effects come from the drug itself or from expectations.
Safety Considerations and Future Directions
Nitrous oxide should not be used outside a medical setting. Without proper monitoring, there is risk of oxygen deprivation, and repeated use can cause vitamin B12 deficiency and anemia. Although the new data are promising, the research is still early. Larger studies, better blinding methods, and long-term safety data are needed before nitrous oxide could be considered a clinical option for treatment-resistant depression.
Still, the interest in nitrous oxide for depression reflects a broader trend in interventional psychiatry. As scientists learn more about brain circuits involved in mood, new fast-acting treatments that target glutamate signaling could offer hope for people who do not benefit from traditional antidepressants.
Read more like this at Interventional Psychiatry Network and subscribe to our newsletter to stay up to date.
Citations
- Wei, Y., et al. Nitrous oxide for treatment-resistant depression: a systematic review and meta analysis. eBioMedicine. https://doi.org/10.1016/j.ebiom.2023.104761
- Zanos, P., et al. Mechanisms of ketamine action as an antidepressant. Molecular Psychiatry. https://doi.org/10.1038/mp.2017.255